Phase 2 Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older who are on maintenance hemodialysis three times per week and still produce some urine
- People who are willing and able to give informed consent to participate
- Women who could become pregnant must have a negative pregnancy test at the screening stage
Who may not be able to join:
- People who do not have the mental capacity to give informed consent
- People who produce less than 200 mL of urine per day (very little to no urine output)
- People who have a kidney transplant planned within the next 3 months
- People who have frequent urinary tract infections (more than 2 per year) or who take antibiotics regularly to prevent them
- People with very severe heart failure (the most serious category, known as Class IV)
- People who have had a heart attack, serious chest pain, heart bypass or stent procedure, or a stroke within the past 12 weeks
- People with a history of a serious diabetes-related complication called diabetic ketoacidosis
- People with Type 1 Diabetes
- People with a rare inherited condition affecting how the body absorbs certain sugars, or a condition causing the kidneys to release glucose into urine abnormally
- People with liver disease, or abnormal liver blood test results above certain levels (unless due to a specific harmless condition called Gilbert's disease)
- People currently being treated for cancer with chemotherapy, radiation, or immunotherapy, or receiving palliative cancer treatment (skin cancers such as squamous cell, basal cell carcinoma, and cervical carcinoma in situ are exceptions)
- People who have had major surgery within the past 12 weeks
- People who have had a non-injury-related amputation in the past 12 months, or who have had an open skin ulcer, bone infection, gangrene, or serious reduced blood flow in the lower limbs within the past 6 months
- People currently taking both an ACE inhibitor and an ARB together (two types of blood pressure medicines)
- People who have taken an SGLT2 inhibitor medication within the 6 weeks before joining the trial
- People with a known allergy or intolerance to SGLT2 inhibitor medicines or their ingredients
- People who have taken part in another clinical drug or device trial within the past 12 weeks
- People who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
- Women who could become pregnant and are unwilling to use a highly effective form of contraception, or who are unwilling or unable to be tested for pregnancy
- People where the trial doctor believes participation would not be in that person's best interest (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: David Charytan, MS, MSc, NYU Langone Health
Phone: 617-935-1572
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Extracellular Volume from Baseline to 12 Weeks; Change in Intracellular Volume from Baseline to 12 Weeks; Change in Total Body Water from Baseline to 12 Weeks; Change in 24-Hour Urine Volume from Baseline to 12 Weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.